NFX vs. EVG, MTFB, DEST, BSFA, GENF, ROQ, VAL, RENE, SALV, and ONC
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), BSF Enterprise (BSFA), Genflow Biosciences (GENF), Roquefort Therapeutics (ROQ), ValiRx (VAL), ReNeuron Group (RENE), SalvaRx Group (SALV), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.
Nuformix vs. Its Competitors
Evgen Pharma (LON:EVG) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Nuformix is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.
Nuformix's return on equity of -5.68% beat Evgen Pharma's return on equity.
27.8% of Evgen Pharma shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 32.4% of Evgen Pharma shares are owned by insiders. Comparatively, 12.4% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Nuformix has a consensus target price of GBX 293, suggesting a potential upside of 366,150.00%. Given Nuformix's stronger consensus rating and higher possible upside, analysts clearly believe Nuformix is more favorable than Evgen Pharma.
In the previous week, Evgen Pharma's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.
Evgen Pharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Nuformix has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
Summary
Nuformix beats Evgen Pharma on 7 of the 11 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 8/23/2025 by MarketBeat.com Staff
MarketBeat All Access